Scott Hensley
Stories
-
An FDA panel of experts backs J&J COVID vaccine booster
A panel of experts voted to recommend that the Food and Drug Administration authorize a booster dose of the Johnson & Johnson COVID vaccine at least two months after the first shot.
-
Experts recommend that FDA should authorize Moderna COVID vaccine booster
The recommendation applies to people 65 years and older, those 18 to 64 who are high risk of severe COVID and those whose work or institutional exposure puts them at high COVID risk.
-
FDA analysis of J&J COVID vaccine booster sets the stage for public hearing
Johnson & Johnson has asked the Food and Drug Administration to authorize a booster for people 18 and older six months after initial immunization, with an option to vaccinate after two months.
-
Moderna and J&J say their data supports COVID vaccine boosters
The Food and Drug Administration released briefing documents Tuesday on booster shots for the Moderna and Johnson & Johnson COVID vaccines ahead of a two-day advisory meeting that starts Thursday.
-
The FDA OKs Pfizer-BioNTech Booster For People 65+ And At High Risk For Severe COVID
A third shot of the vaccine can be given at least six months after the two-dose regimen, according to the authorization. A booster rollout could begin this week.
-
Experts Advising FDA Vote Against Pfizer COVID Booster
A panel of advisers to the Food and Drug Administration voted against approval of a booster dose of the Pfizer-BioNTech COVID-19 vaccine for people 16 years and older.
-
Pfizer Analysis Makes Case For COVID Vaccine Booster
Pfizer says data support its request for Food and Drug Administration approval of a third dose of COVID vaccine about six months after the second dose in people 16 years and older.
-
Pfizer's COVID Vaccine Gets Full Approval From The FDA
The approval replaces the emergency use authorizations granted last December, and could make it easier for employers, the military and universities to mandate the vaccination.
-
The FDA Has Approved A New Alzheimer's Drug — Here's Why That's Controversial
This is the first new drug approved for Alzheimer's disease since 2003. It's the first to show significant progress against the sticky brain plaques that are the hallmark of Alzheimer's disease.
-
Latest AstraZeneca Report Supports Effectiveness Of COVID Vaccine
Updated study results say the vaccine is 76% effective against symptomatic COVID-19 and 100% effective against severe disease. Independent monitors had been concerned about a previous report.